Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phenylalanine (Phe) Clear all
Withdrawn Phase 2 Interventional

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01055301
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
21
States / cities
Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 7, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

NCT06028828
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
Interventions
Fludarabine, Melphalan, Total Body Irradiation
Drug · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 7, 2026, 2:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stable Isotopes- Adults With Obesity

NCT07020741
View directory record Official record
Conditions
Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
Interventions
Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test
Procedure
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
19 Years to 59 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

NCT00145626
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Histiocytosis
Interventions
Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
Drug · Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 7, 2026, 2:53 AM EDT
Terminated Phase 2 Interventional Results available

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

NCT04205240
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Daratumumab, Fludarabine, Melphalan, Mycophenolate Mofetil, Tacrolimus
Procedure · Drug · Biological
Lead sponsor
Srinivas Devarakonda
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

NCT00349778
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 7, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

NCT06607458
View directory record Official record
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Duarte, California • Santa Monica, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time Course of Postprandial Protein Metabolism

NCT04121689
View directory record Official record
Conditions
Muscle Protein Synthesis, Protein Metabolism
Interventions
Milk Protein Concentrate
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 7, 2026, 2:53 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

NCT04282174
View directory record Official record
Conditions
Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions
CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine
Device · Procedure · Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
Up to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 7, 2026, 2:53 AM EDT
Terminated Phase 3 Interventional Results available

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

NCT02489500
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bortezomib, Melphalan, Neupogen, Stem Cell Collection, Stem cell infusion
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Levodopa for Diabetic Retinopathy

NCT07444892
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 7, 2026, 2:53 AM EDT
Not listed Early Phase 1 Interventional

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

NCT04315584
View directory record Official record
Conditions
Glioblastoma
Interventions
Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa
Procedure · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 7, 2026, 2:53 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

NCT02756728
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BI-505, High dose melphalan, Autologous stem cell transplantation
Biological · Other
Lead sponsor
BioInvent International AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00004165
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

NCT00943592
View directory record Official record
Conditions
Advanced Hematologic Malignancies, Leukemia, Preleukemia
Interventions
Clofarabine, Melphalan, Campath, Stem Cell Transplant
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

NCT01200329
View directory record Official record
Conditions
Lymphoma
Interventions
Gemcitabine, Busulfan, Melphalan, Stem Cell Transplantation, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 7, 2026, 2:53 AM EDT
Not listed Phase 1 Interventional

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

NCT00436761
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, busulfan, cyclosporine, melphalan, methylprednisolone, flow cytometry, immunologic technique, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

NCT05592951
View directory record Official record
Conditions
Safety, Tolerance
Interventions
Crystal Light (once serving), Liquid IV with amino acids (one serving), Liquid IV with amino acids (two servings), Liquid IV with amino acids (three servings)
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 7, 2026, 2:53 AM EDT
Withdrawn No phase listed Observational

Natural History of Levodopa-Induced Dyskinesia (LID)

NCT01003002
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa (delivered intravenously)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

NCT00789256
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Interventions
Melphalan, Bortezomib, Melphalan and bortezomib
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Jacksonville, Florida • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 7, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide, Total Body Irradiation
Drug · Procedure · Biological + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 7, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

NCT00003662
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 2 Interventional

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02570542
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 7, 2026, 2:53 AM EDT